Common Phthalate Tied to Coronary Risk in Car Plant Workers
Exposure to monoethyl phthalate (MEP) — a chemical commonly found in industrial and personal care products — was associated with a substantially elevated risk for subclinical coronary atherosclerosis among men working in a car assembly unit.
METHODOLOGY:
Researchers conducted a cross-sectional study to assess whether urinary phthalates showed any association with subclinical coronary atherosclerosis.
They included 1119 Spanish male workers (mean age, 50.9 years) from a car assembly plant.
A total of 11 urinary phthalate metabolites were measured using liquid chromatography coupled to tandem mass spectrometry.
Participants underwent CT scans between January 2011 and December 2014 to determine coronary artery calcium; subclinical coronary atherosclerosis was defined as a coronary artery calcium score ≥ 100 Agatston units.
TAKEAWAY:
Subclinical coronary atherosclerosis was identified in 114 men (10.2%).
MEP was the phthalate with the highest median concentration; men with subclinical coronary atherosclerosis had a higher median MEP concentration than those without the condition (126.1 vs 99.3 µg/g creatinine).
Each 1-unit increase in the natural logarithm of MEP was associated with a 21% higher prevalence of subclinical coronary atherosclerosis (adjusted odds ratio, 1.21; 95% CI, 1.02-1.44).
Monoisobutyl phthalate and mono-n-butyl phthalate showed a positive association with the condition, but this association did not reach statistical significance.
IN PRACTICE:
"Educational strategies might complement cardiovascular prevention by promoting behaviors that reduce phthalate exposure, such as choosing fragrance-free products, preferring glass containers over plastics, and minimizing ultraprocessed food consumption," the researchers noted.
SOURCE:
This study was led by Diana María Mérida, Universidad Autónoma de Madrid, Madrid, Spain. It was published online on August 06, 2025, in The American Journal of Preventive Cardiology.
LIMITATIONS:
This cross-sectional study could not imply whether phthalates caused subclinical coronary atherosclerosis. The findings may not be generalisable to women, older adults, or individuals from different occupational backgrounds or socioeconomic groups. Urinary concentrations of phthalate metabolites reflect only short-term exposure, but chronic diseases are usually linked to long-term exposures.
DISCLOSURES:
This study was supported by the Health Research Fund from the State Secretary of R+D and FEDER/FSE, Instituto de Salud Carlos III, Spain. The authors reported having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Drug that slows onset of type 1 diabetes licensed for use in UK-first
A groundbreaking drug that slows down the development of type 1 diabetes has been licensed for use in the UK. Teplizumab can allow patients to live 'normal lives' without the need for insulin injections. Experts hailed the decision by the Medicines and Healthcare Regulatory Agency (MHRA) as a 'breakthrough moment' that represents a 'turning point' in how the condition is treated. About 400,000 people in the UK have type 1 diabetes, a lifelong condition which causes the immune system to attack insulin-producing cells in the pancreas. Insulin helps the body use sugar for energy, and without this hormone, blood sugar levels can become dangerously high. Type 1 diabetes needs constant management to keep blood sugar within range, with patients required to take insulin through injections or pumps. Teplizumab trains the immune system to stop attacking pancreatic cells. It is taken by an IV drip for a minimum of 30 minutes over 14 consecutive days. The drug, which is already approved in the US, has been authorised for use by the MHRA to delay the onset of stage three type 1 diabetes in adults and children aged eight or over by an average of three years. Ahmed Moussa, general manager of general medicines UK and Ireland at Sanofi, which makes teplizumab, said: 'One hundred years ago the discovery of insulin revolutionised diabetes care. Today's news marks a big step forward.' The UK is the first country in Europe to be granted a licence. Type 1 diabetes develops gradually in three stages over months or years. Stage three is usually when people start to experience blood sugar problems and are diagnosed with the condition. According to the MHRA, teplizumab is used in people with stage two type 1 diabetes, which is an earlier stage of the disease during which patients are at a high risk of progressing to stage three. Parth Narendran, a professor of diabetes medicine at the University of Birmingham and The Queen Elizabeth Hospital Birmingham, said: 'Teplizumab essentially trains the immune system to stop attacking the beta cells in the pancreas, allowing the pancreas to produce insulin without interference. 'This can allow eligible patients to live normal lives, delaying the need for insulin injections and the full weight of the disease's daily management by up to three years. It allows people to prepare for disease progression rather than facing an abrupt emergency presentation.' Following the decision by the MHRA, the cost-effectiveness of teplizumab will be assessed by NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to determine if it can be rolled out on the health service. Karen Addington, chief executive of the charity Breakthrough T1D, said: 'I am personally delighted and welcome the MHRA's approval of teplizumab. 'After years of research, clinical trials and drug development, we have an incredible breakthrough.' Reacting to the announcement, Dr Elizabeth Robertson, director of research and clinical at Diabetes UK, said: 'Today's landmark licensing of teplizumab in the UK marks a turning point in the treatment of type 1 diabetes. 'For the first time, we have a medicine that targets the root cause of the condition, offering three precious extra years free from the relentless demands of managing type 1 diabetes.' Dr Robertson added that the 'next steps are critical'. 'To ensure teplizumab reaches everyone who could benefit, we need it to be made available on the NHS, and the rollout of a screening programme to identify those with early-stage type 1 diabetes,' she said.
Yahoo
an hour ago
- Yahoo
Lilly raises UK obesity shot price as Trump pressures pharma
(Bloomberg) — Eli Lilly & Co. is raising the list price for its obesity shot in the UK by as much as 170%, as the pharma industry comes under pressure from US President Donald Trump to increase medicine prices in Europe and lower them for Americans. The current list price in the UK for Lilly's Mounjaro ranges from £92 ($124.89) to £122 a month, depending on the dose. This will increase to between £133 and £330 from Sept. 1, with the US drugmaker saying it aims to bring rates in line with other countries. Trump sent letters to 17 of the world's largest drugmakers earlier this month, including Lilly and Novo Nordisk A/S, which makes the competing shot Wegovy, insisting they lower what they charge Medicaid in the US for existing drugs. He gave the companies 60 days to comply, saying he wants companies to negotiate harder with 'foreign freeloading nations' who pay less for their medicines. Lilly said the increase follows a review that looked to address pricing inconsistencies. The UK was one of the first countries where Mounjaro was introduced, with rates 'significantly below the European average to prevent delays' in availability via the National Health Service, the company added. 'With changes in the environment and new clinical evidence supporting the value of Mounjaro, Lilly are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation,' it said. Affordability Concerns The new list price is still well below the level in the US, where it costs over $1,000 a month. Still, the higher prices raised concerns in online forums from patients who say the drug will be unaffordable for them. Patients in the UK usually get most medicines on the National Health Service for a set prescription price of £9.90. However, obesity drugs have only just started to be rolled out on the NHS and the criteria for access are stringent. So far, the majority of patients who access the weight-loss shots have been doing so privately. The actual price that these patients pay is likely to be well below the list price, because Lilly negotiated commercial agreements with private providers. Still, those providers are likely to face difficult decisions on how much to pass on any price increase to patients. Pharmacies like Walgreens Boots Alliance Inc.'s Boots and Superdrug, as well as online providers like Juniper and Voy that have focused on weight-loss drugs, have benefited from the rush for obesity shots. If patients are unable to afford more expensive Mounjaro, they may also switch to Novo's Wegovy. Novo has not yet announced a similar increase in price for its obesity drug. While the list price has increased, Lilly said it is working with private providers to maintain access for patients. Separately, the company reached an agreement with the NHS to ensure continued supply and patient access. —With assistance from Madison Muller. (Updates with more detail on pharmacies selling the shots, from paragraph nine) ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Gizmodo
an hour ago
- Gizmodo
A Common Virus Causes Cancer, but Most Americans Are Clueless About It
The human papillomavirus (HPV) is a major source of cancer that's now almost entirely preventable through vaccination. But sobering research out today shows that Americans are largely in the dark about HPV and its many health risks, much less the HPV vaccine. Researchers at the Medical University of South Carolina conducted the study, which examined nationally representative survey data. A third of Americans don't know that the virus exists, they found, while most who do know are still unaware it can cause more than one type of cancer besides cervical cancer. People in certain regions of the country, particularly Midwest and Southern states, were even less aware of HPV, which likely helps explain why vaccination rates are lagging in these areas, the researchers say. 'Some of these states have the lowest HPV vaccine coverage in the nation, which could be a reason why we are observing these differences,' lead study author Ashvita Garg, a public health researcher at MUSC, told Gizmodo. There are over 200 different types of HPV, which is spread through skin contact (including sexual contact). Some types are low-risk, only causing unseemly but harmless warts along our skin or genitals. Other high-risk types can linger in the body and cause damaging changes to normal cells that raise their risk of becoming cancerous. HPV is the leading cause of cervical cancer, accounting for nearly all cases. But high-risk HPV infections are also primarily responsible for several other kinds of cancer, including vaginal and vulvar cancers in women, penile cancer in men, and oral cancer in both men and women. In fact, HPV-related oral cancer is more common in men than it is in women. All told, about 40,000 HPV-caused cancers occur annually in the U.S. Today's vaccines can prevent up to nine different high-risk types of HPV, but the vaccination rate remains relatively low in many parts of the world, the U.S. included. The researchers sought to better understand just how aware people are about the virus and the value of vaccination. The researchers studied data from the Health Information National Trends Survey (HINTS), a project run by the National Cancer Institute that regularly measures Americans' knowledge of health and cancer-related information. Their sample ultimately included almost 23,000 responses collected between 2017 and 2022. Based on the survey data, around 34% of Americans nationally were ignorant about the existence of HPV, and 37% were ignorant about the HPV vaccine. Of those who did know about the virus, 71% didn't know that it can cause oral cancer, and 28% didn't know it caused cervical cancer. Ignorance of HPV and the vaccine was especially high (over 40%) in seven states, including Kansas, Nebraska, and Illinois in the Midwest, as well as Mississippi, Arkansas, and Alabama in the South. These same states have some of the lowest HPV vaccination rates in the country, and about 62% of all HPV-related cancers occur in the Southern and Midwestern U.S., the authors note. 'Additionally, the gap between awareness that HPV causes oral cancer was notably larger compared to the awareness that HPV causes cervical cancer, highlighting the undervaluation of the importance of HPV vaccination in males,' Garg said. The team's findings were published Thursday in JAMA Oncology. Some countries have already started to effectively eliminate cervical and other HPV-related cancers through widespread HPV vaccination, but the U.S. is still lagging well behind. Overall, only around 57% of American teenagers in 2023 received the HPV vaccine as recommended, well below the 80% target goal that health officials are hoping to reach by 2030. The researchers say that much more effort is needed to improve people's knowledge of HPV and its dangers. 'Improving HPV awareness would require a multifaceted approach, such as public education campaigns, improving patient-provider communication, and community and school-based outreach programs,' Garg said. Unfortunately, the federal government may not be so interested in HPV prevention these days. Robert F. Kennedy Jr., the current health secretary, has regularly spread misinformation about the HPV vaccine and even referred to Merck's HPV shot, Gardasil, as the 'most dangerous vaccine ever invented.' All that said, Garg and her team at MUSC are still dedicated to improving HPV vaccine coverage in their neck of the woods. 'Beyond examining the HPV-related cancer burden and mortality, we are also investigating the uptake and delivery of HPV prevention modalities and understanding prevention behaviors across the US,' she said. 'MUSC is also actively involved in public health outreach, particularly in South Carolina, where initiatives like the HPV Vaccination Van are helping to improve education and access to HPV vaccination.'
